Practice parameter A focused parameter update : Hereditary angioedema , acquired C 1 inhibitor deficiency , and angiotensin-converting enzyme inhibitor – associated angioedema

Disclosure of potential conflict of interest: B. L. Zuraw has received research support from Shire, theNational Institutes of Health (NIH), theDepartment of Defense (DOD), and the Veterans’ Administration; is the chair of themedical advisory board for the Hereditary Angioedema Association, and has consultant arrangements with CSL Behring, Dyax, Isis, and Biocryst. J. A. Bernstein is a partner in the Bernstein Allergy Group and a member of Bernstein Clinical Research; has received research support from Dyax, Shire, CSL Behring, ViroPharma, Pharming, and Novartis; is on the Board of Directors for the American Academy of Allergy, Asthma & Immunology (AAAAI), is a fellow of the American College of Allergy, Asthma & Immunology (ACAAI), is Chairman of Allergists for Israel, and is on the advisory board for the Hereditary Angioedema Association; is Editor in Chief of the Journal of Asthma; serves on the Editorial Boards for the Journal of Allergy and Clinical Immunology, the Annals of Allergy, Allergy Proceedings, and the Journal of Angioedema; and is the Editor of the Joint Task Force Guidelines on Urticaria and Angioedema. D. M. Lang serves on the Board of Directors for the AAAAI; is a member of the Pulmonary and Critical Care Steering Committee of the National Quality Forum; is a speaker for Genentech/ Novartis, GlaxoSmithKline, and Merck; is a consultant for GlaxoSmithKline, Merck, and Aerocrine; and has received research support from Genentech/Novartis and Merck. T. Craig is an interest section leader for the AAAAI, is a board member for the ACAAI, the American Lung Association–Pennsylvania, and the Joint Council of Allergy, Asthma and Immunology; has consultant arrangements with CSL Behring, Dyax, Viropharma, and Shire; has provided expert testimony in cases related to anaphylaxis; has received grants from Viropharma, CSL Behring, Shire, Dyax, Pharming, Forrest, Genentech, Biota, GlaxoSmithKline, and Grifols; has received payment for lectures from Viropharma, CSL Behring, Dyax, Merck, Novartis, Genentech, and TEVA; and has received payment for development of educational presentations from the Vietnam Education Foundation. F. Hsieh has received a research grant from the Howard Hughes Medical Institute. D. Khan has speaker arrangements with Genentech, Merck, Baxter, and Viropharma; has received research support from the Vanberg Family Foundation and the NIH/National Institute of Mental Health; is the Allied Health Chair for the ACAAI, and is a member of the Joint Task Force on Practice Parameters for the Joint Council of Allergy, Asthma, and Immunology. J. Sheikh has consultant arrangements with CSL Behring; has consulted in cases related to allergy/immunology medical malpractice; is a member of the ACAAI; is on the Executive Board for the Massachusetts Allergy Society; and is on the Executive Board and is CMEDirector for the NewEngland Society of Allergy. D.Weldon has provided expert testimony on behalf of the Texas Allergy, Asthma, and Immunology Society; is on the Board of Regents for the ACAAI; and is chair of the Practice Standards Committee for the Texas Allergy, Asthma, and Immunology Society. D. I Bernstein has received research support from TEVA, Genentech, Pfizer, Merck, Meda, GlaxoSmithKline, ARRAY, Cephalon, and MedImmune and has provided legal consultation services or expert witness testimony in cases related to anaphylaxis, contact dermatitis, and and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing ‘‘A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-